Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:49.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has been updated to include new collaborators, specifically Eli Lilly and Company, and a revision number change from v2.14.4 to v2.15.0. Additionally, the title of the study has been modified to emphasize the focus on Head and Neck Squamous Cell Carcinoma.
    Difference
    32%
    Check dated 2025-04-16T02:01:23.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 27, 2024.
    Difference
    0.5%
    Check dated 2025-04-08T22:24:43.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T18:21:35.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-03-03T22:18:58.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:43:46.000Z thumbnail image

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.